Search

Search results for ""

Drug name	NICE TAs	Comments
Nintedanib#8.1	TA347 - Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer
Niraparib	TA528 - Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer TA673 - Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
Nirmatrelvir plus ritonavir (Paxlovid®)	TA878 - Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
Nitazoxanide
Nitisinone capsules
Nitrous oxide
Nivolumab (Opdivo®)	TA384 - Nivolumab for treating advanced (unresectable or metastatic) melanoma TA400 - Nivolumab in combination with ipilimumab for treating advanced melanoma TA417 - Nivolumab for previously treated advanced renal cell carcinoma TA462 - Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma TA483 - Nivolumab for previously treated squamous non-small-cell lung cancer TA484 - Nivolumab for previously treated non-squamous non-small-cell lung cancer TA490 - Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy TA558 - Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease TA581 - Nivolumab with ipilimumab for untreated advanced renal cell carcinoma TA655 - Nivolumab for advanced squamous non-small cell lung cancer after chemotherapy TA684 - Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease TA707 - Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer TA713 - Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy TA716 - Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency TA736 - Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy TA746 - Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer TA817 - Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence TA818 - Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma TA857 - Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma TA865 - Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma TA876 - Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer
Nizatidine
Nonacog beta pego (Refixia®)		NHSE Commissioned
Norgeston		Umbrella service only

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Search results for ""